cece

*April 2021* In this podcast, Drs. H. Jack West, Helena Yu, and David Spigel discuss the addition of SBRT to a systemic EGFR inhibitor TKI in EGFR positive NSCLC. Listen here.

*April 2021* In this podcast, Drs. H. Jack West, Helena Yu, and David Spigel discuss the addition of SBRT to a systemic EGFR inhibitor TKI in EGFR positive NSCLC. Listen here.

*April 2021* Jyoti D. Patel, MD, discusses how the FDA approval of adjuvant osimertinib has impacted the treatment of patients with EGFR-positive NSCLC, efforts being made to overcome resistance to the third-generation EGFR TKI, and other approaches under exploration that may serve to further improve outcomes in this population. Read…

*April 2021* Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on EGFR TKI treatment. Here, we review the mechanisms of acquired…

*April 2021* During the past decade, evidence has been building that non–small cell lung cancer (NSCLC) has a distinct clinical and genomic profile in patients 40 years and younger. Now investigators have launched the Epidemiology of Young Lung Cancer (EoYLC) study (NCT04640259) to identify risk factors that can help shed…

*April 2021* Single-agent telisotuzumab vedotin (teliso-v; ABBV-399) induced an encouraging objective response rate (ORR) with a tolerable safety profile in patients with previously treated non–small cell lung cancer (NSCLC) who were c-MET positive, according to data from a phase 2 study (NCT03539536) presented in a virtual poster during the AACR…

*April 2021* NOTE: In a small percentage of EGFR+ lung cancer patients, transformation to SCLC can occur, perhaps as a resistance mechanism. Oncologists tend to treat SCLC transformation the same as de novo SCLC, but sometimes osimertinib is continued along with SCLC treatment. This article refers to de novo SCLC treatments, not…

*April 2021* The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy. Read more.

*March 2021* Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer. Listen here.